Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Eocene Ltd. (EOCN : NSDQ)

• Company Description    EoCene Ltd. is a GI-focused medtech and biopharmaceutical company. It building a diversified platform which combines medical devices, therapeutics and enabling technologies to address significant unmet clinical needs and improve patient outcomes. Its flagship product includes CG-100. EoCene Ltd., formerly known as Galmed Pharmaceuticals, is based in RAMAT-GAN, Israel. Number of Employees: 9

• Price / Volume Information    Yesterday's Closing Price: $3.12 Daily Weekly Monthly 20 Day Moving Average: 7,563 shares Shares Outstanding: 1.04 (millions) Market Capitalization: $3.25 (millions) Beta: 0.66 52 Week High: $12.32 52 Week Low: $2.33 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -13.84% -14.41% 12 Week -30.34% -34.30% Year To Date -48.05% -54.16%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 16 ABBA HILLEL ROAD - RAMAT GAN,L3 5250608 ISR ph: 972-3693-8448 fax: 972-3693-8447 investor.relations@galmedpharma.com http://www.galmedpharma.com

• General Corporate Information    Officers Allen Baharaff - Chief Executive Officer and President Guy Nehemya - Chief Operating Officer and Data Protection Office Doron Cohen - Chief Financial Officer Yohai Stenzler - Chief Accounting Officer Shmuel Nir - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: M47238205 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/26 Next Expected EPS Date: 11/25/26 Share - Related Items Shares Outstanding: 1.04 Most Recent Split Date: 8.00 (0.13:1) Beta: 0.66 Market Capitalization: $3.25 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/25/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.20 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 43.25% vs. Previous Quarter: -23.28% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 09/30/26 - - 06/30/26 - -73.68 03/31/26 - -64.10 ROA 09/30/26 - - 06/30/26 - -60.88 03/31/26 - -56.15 Current Ratio 09/30/26 - - 06/30/26 - 4.16 03/31/26 - 7.71 Quick Ratio 09/30/26 - - 06/30/26 - 4.16 03/31/26 - 7.71 Operating Margin 09/30/26 - - 06/30/26 - - 03/31/26 - - Net Margin 09/30/26 - - 06/30/26 - - 03/31/26 - - Pre-Tax Margin 09/30/26 - - 06/30/26 - - 03/31/26 - - Book Value 09/30/26 - - 06/30/26 - 15.44 03/31/26 - 16.91 Inventory Turnover 09/30/26 - - 06/30/26 - - 03/31/26 - - Debt-to-Equity 09/30/26 - - 06/30/26 - 0.00 03/31/26 - 0.00 Debt-to-Capital 09/30/26 - - 06/30/26 - 0.00 03/31/26 - 0.00

Powered by Zacks Investment Research ©